BIOMAT Database Logo BIOMAT Database Logo

[Perspectives in anti-arrhythmia pharmacological therapy]. 1984

F Furlanello, and G Vergara, and G Inama, and P Dal Forno, and R Bettini, and M Disertori

UI MeSH Term Description Entries
D008012 Lidocaine A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE. Lignocaine,2-(Diethylamino)-N-(2,6-Dimethylphenyl)Acetamide,2-2EtN-2MePhAcN,Dalcaine,Lidocaine Carbonate,Lidocaine Carbonate (2:1),Lidocaine Hydrocarbonate,Lidocaine Hydrochloride,Lidocaine Monoacetate,Lidocaine Monohydrochloride,Lidocaine Monohydrochloride, Monohydrate,Lidocaine Sulfate (1:1),Octocaine,Xylesthesin,Xylocaine,Xylocitin,Xyloneural
D002304 Cardiac Pacing, Artificial Regulation of the rate of contraction of the heart muscles by an artificial pacemaker. Pacing, Cardiac, Artificial,Artificial Cardiac Pacing,Artificial Cardiac Pacings,Cardiac Pacings, Artificial,Pacing, Artificial Cardiac,Pacings, Artificial Cardiac
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004594 Electrophysiology The study of the generation and behavior of electrical charges in living organisms particularly the nervous system and the effects of electricity on living organisms.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D001145 Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction. Arrhythmia,Arrythmia,Cardiac Arrhythmia,Cardiac Arrhythmias,Cardiac Dysrhythmia,Arrhythmia, Cardiac,Dysrhythmia, Cardiac
D016677 Tocainide An antiarrhythmic agent which exerts a potential- and frequency-dependent block of SODIUM CHANNELS. Tocainide Hydrochloride,Tocainide Monohdyrochloride, (R)-Isomer,Tocainide Monohydrobromide, (R)-Isomer,Tocainide Monohydrochloride,Tocainide Monohydrochloride, (+-)-Isomer,Tocainide Monohydrochloride, (S)-Isomer,Tocainide, (+-)-Isomer,Tocainide, (R)-Isomer,Tocainide, (S)-Isomer,Tonocard,W-36095,Xylotocan,Hydrochloride, Tocainide,W 36095,W36095

Related Publications

F Furlanello, and G Vergara, and G Inama, and P Dal Forno, and R Bettini, and M Disertori
[Perspectives of pharmacological anti-proliferative therapy for arteriosclerosis].
October 2003, Recenti progressi in medicina,
F Furlanello, and G Vergara, and G Inama, and P Dal Forno, and R Bettini, and M Disertori
[Anti-arrhythmia therapy in transition?].
March 1990, Der Internist,
F Furlanello, and G Vergara, and G Inama, and P Dal Forno, and R Bettini, and M Disertori
[Combination anti-arrhythmia therapy].
May 1993, Der Internist,
F Furlanello, and G Vergara, and G Inama, and P Dal Forno, and R Bettini, and M Disertori
[Current anti-arrhythmia therapy].
March 1994, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
F Furlanello, and G Vergara, and G Inama, and P Dal Forno, and R Bettini, and M Disertori
[Arrhythmia and anti-arrhythmia therapy as prognostic risks].
September 1991, Herz,
F Furlanello, and G Vergara, and G Inama, and P Dal Forno, and R Bettini, and M Disertori
[Anti-arrhythmia therapy in the elderly].
December 1986, Cardiologia (Rome, Italy),
F Furlanello, and G Vergara, and G Inama, and P Dal Forno, and R Bettini, and M Disertori
[Recent trends in anti-arrhythmia therapy].
March 1995, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
F Furlanello, and G Vergara, and G Inama, and P Dal Forno, and R Bettini, and M Disertori
[New concepts in anti-arrhythmia therapy].
February 1970, Turk Tip Cemiyeti mecmuasi,
F Furlanello, and G Vergara, and G Inama, and P Dal Forno, and R Bettini, and M Disertori
[Difficulties of anti-arrhythmia therapy].
January 1979, Terapevticheskii arkhiv,
F Furlanello, and G Vergara, and G Inama, and P Dal Forno, and R Bettini, and M Disertori
[Flecainide and anti-arrhythmia therapy].
March 1988, Minerva medica,
Copied contents to your clipboard!